ArticleEuropean journal of gastroenterology & hepatology2025
Distinct composition and metabolic potential of biliary microbiota in patients with malignant bile duct obstruction.
Article in European journal of gastroenterology & hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microbial dysbiosis in cholangiocarcinoma.Frontiers in microbiology · 2026Review
- Taurine Alleviates Inflammation, Oxidative Stress, Apoptosis, and Uterus Microbiota Dysregulation of Endometritis by Inhibiting PI3K-AKT/MAPK/NF-κB Pathways in Mice.Animals : an open access journal from MDPI · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging evidence highlights the role of biliary microbiota in hepato-biliary-pancreatic diseases. The characteristics of biliary microbiota in malignant bile duct obstruction remain poorly understood. This study aims to investigate the composition and metabolic functions of biliary microbiota in patients with malignant obstruction.
methodsEligible patients were enrolled in this prospective study at First Affiliated Hospital of Soochow University between December 2022 and October 2023, including distal cholangiocarcinoma, hilar cholangiocarcinoma, pancreatic ductal adenocarcinoma, periampullary carcinoma, and gallbladder carcinoma. The patients with choledocholithiasis served as controls. Bile samples were collected via endoscopic retrograde cholangiopancreatography. Microbiota identification was performed using 16S rRNA sequencing, while bile acids were analyzed using mass spectrometry.
resultsA total of 56 patients were successfully enrolled in this study, 25 in the tumor group and 31 in the stone group. A distinct biliary microbial community was observed in patients with malignant bile duct obstruction, consisting of Prevotella, Uruburuella, Atopostipes, Clostridium IV, Halomonas, Tannerella, Porphyromonas, Achromobacter, Rouxiella, Campylobacter, Corynebacterium, Turicibacter, Muribaculum, Selenomonas, and Alloprevotella at genus level. Notably, Clostridium IV, Halomonas, Rouxiella, and Turicibacter were exclusively present in the tumor group. Bile acid levels were significantly lower in the tumor group (P < 0.05), except for ursodeoxycholic acid and taurocholic acid. Additionally, 22 metabolic pathways were enriched in the tumor group.
conclusionsThis study elucidates the community and metabolic potential of biliary microbiota in malignant bile duct obstruction. The findings offer valuable insights for disease assessment and provide a foundation for further research into the role of biliary microbiota in malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.